Cargando…
The Assessment of Convalescent Plasma Efficacy against COVID-19
Antibody-based therapy for infectious diseases predates modern antibiotics and, in the absence of other therapeutic options, was deployed early in the SARS-CoV-2 pandemic through COVID-19 convalescent plasma (CCP) administration. Although most studies have demonstrated signals of efficacy for CCP, d...
Autores principales: | Casadevall, Arturo, Grossman, Brenda J., Henderson, Jeffrey P., Joyner, Michael J., Shoham, Shmuel, Pirofski, Liise-anne, Paneth, Nigel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747676/ https://www.ncbi.nlm.nih.gov/pubmed/33363284 http://dx.doi.org/10.1016/j.medj.2020.11.002 |
Ejemplares similares
-
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022) -
Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy
por: Casadevall, Arturo, et al.
Publicado: (2020) -
Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence
por: Klassen, Stephen A., et al.
Publicado: (2021) -
Rethinking the role of COVID-19 convalescent plasma in the critically ill
por: Casadevall, Arturo, et al.
Publicado: (2023) -
Use of convalescent plasma in the treatment of COVID-19
por: Joyner, Michael J., et al.
Publicado: (2023)